Marker Therapeutics Inc (MRKR NASDAQ) stock market data APIs
$1.8282
0(0%)
as of February 4, 2026
Try our APIs with
free plan!
Marker Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Prev. Close
1.8282
Open
1.829
High
1.829
Low
1.7212
52 wk Range
0.8099-2.46
Market Cap
23 549 K
Shares Outstanding
12 939 K
Revenue
4 695 K
EPS
-0.12
Beta
1.41
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Marker Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Marker Therapeutics Inc data using free add-ons & libraries
Get Marker Therapeutics Inc Fundamental Data
Marker Therapeutics Inc Fundamental data includes:
- Net Revenue: 4 695 K
- EBITDA: -11 792 272
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Marker Therapeutics Inc News
New
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics’ MRKR shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted investor c...
High Growth US Tech Stocks To Watch In January 2026
As the U.S. market grapples with heightened geopolitical tensions and the threat of new tariffs, major indices like the Nasdaq and S&P 500 have experienced significant declines, reflecting broader mar...
US High Growth Tech Stocks to Watch
As the U.S. market grapples with rising Treasury yields and uncertainty surrounding Federal Reserve policies, major indexes have posted weekly losses, reflecting a cautious sentiment among investors. ...
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics
For Immediate Release Chicago, IL – January 8, 2026 – Today, Zacks Equity Research discusses Soleno Therapeutics SLNO, Nektar Therapeutics NKTR, Rigel Pharmaceuticals RIGL, Ironwood Pharmaceutica...
Get Marker Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
